Madrid, a two-time survivor of Stage 4 cancer, weaves together his life experiences – including his Italian heritage, the power of family connection, and effective mindset techniques – into an ...
6hon MSN
Increasingly common health conditions raise risk of death from cancer that killed James Van Der Beek
A sweeping analysis of over 50 million people found that a cluster of common health conditions significantly raises the risk ...
On this Valentine's Day, a couple recalls everything they had to overcome from long distance to three cancer diagnoses over ...
Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment ...
Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a ...
Diabetes was associated with an increased risk of pancreatic cystic neoplasms (PCNs), with longer disease duration linked to progressively higher risk, according to a nationwide population-based ...
Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.
NovoCure (NVCR) stock rose 29% Thursday on early FDA approval for Optune Pax pancreatic cancer device, prompting H.C. Wainwright to raise target to $47.
NovoCure shares are popping Thursday following a major FDA approval that sent the stock soaring nearly 30% in Wednesday's ...
A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results